NVASC
NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The company has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. The company is planning to manufacture NVB001 which can be used in toxicokinetic studies and in early clinical trials in humans.
NVASC
Industry:
Health Care Medical Device Therapeutics
Founded:
2019-01-01
Address:
Atherton, California, United States
Country:
United States
Status:
Active
Total Funding:
0
Similar Organizations
RightAir
RightAir is developing noninvasive ventilators for COPD patients.
Current Employees Featured
Founder
Investors List
Kairos Ventures
Kairos Ventures investment in Venture Round - NVasc
More informations about "NVasc"
NVasc - Crunchbase Company Profile & Funding
NVasc is an early-stage ophthalmology company with a focus on treating blindness. It specializes in treating the leading causes of blindness through choroidal and retinal revascularization. The …See details»
NVasc, Inc. - A Kairos Ventures Portfolio Company
NVasc, Inc. is an early-stage ophthalmology company founded in February, 2019 and funded by Kairos Ventures in November, 2919. The company is focused …See details»
NVasc Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for NVasc. Use the PitchBook Platform to explore the full profile.See details»
NVasc - Kairos Ventures
NVasc, Inc. is an early-stage ophthalmology company focused on the treatment of ischemic eye diseases, such as age-related macular degeneration and diabetic retinopathy.See details»
The Retinal Degeneration Fund Announces an Investment in NVasc
NVasc is developing a therapeutic angiogenesis strategy for the treatment of retinal ischemia associated with the continuum of age-related macular degeneration.See details»
The Retinal Degeneration Fund Announces an Investment in NVasc
Oct 16, 2023 · NVasc, Inc. is an early-stage ophthalmology company founded in February 2019 and funded by Kairos Ventures in November 2019. The company is focused on treating the …See details»
NVasc - Funding, Financials, Valuation & Investors - Crunchbase
Oct 16, 2023 · NVasc is an early-stage ophthalmology company with a focus on treating blindness.See details»
NVasc - Mitsui & Co. Global Investment, Inc.
A pre-clinical stage biopharmaceutical company focusing on treating the leading causes of blindness through choroidal and retinal revascularization.See details»
Venture Round - NVasc - 2023-10-16 - Crunchbase
Oct 16, 2023 · Retinal Degeneration Fund Retinal Degeneration Fund makes mission-related investments in therapeutic companies with projects nearing clinical testing.See details»
Ethics in Victim Services - Office of Justice Programs
The concepts discussed in this book are based on the model of ethical standards developed by the National Victim Assistance Standards Consortium (NVASC). Four chapters constitute part …See details»
NVasc - Products, Competitors, Financials, Employees, …
NVasc provides health care services. Use the CB Insights Platform to explore NVasc's full profile.See details»
NVasc - Updates, News, Events, Signals & Triggers - Crunchbase
NVasc is an early-stage ophthalmology company with a focus on treating blindness.See details»
Adrienne Graves, PhD - Glaucoma Research Foundation
Dr. Graves currently serves as an Independent Director on the boards of Harrow, Implandata, JelliSee, NVasc, Ocular Therapeutix, Opus Genetics, Osanni Bio, Surface Ophthalmics, and …See details»
Napoleone Ferrara MD Profile: Contact Information & Network
Information on current and former positions, network members and contacts for Napoleone Ferrara MD. Use the PitchBook Platform to explore the full profile.See details»
The Retinal Degeneration Fund Announces an Investment in NVasc
Oct 16, 2023 · NVasc is developing a therapeutic angiogenesis strategy for the treatment of retinal ischemia associated with the continuum of age-related macular degenerationSee details»
NVB-001 - Drug Targets, Indications, Patents - Synapse
Understand key drug designations in just a few clicks with Synapse. NVB-001, Initially developed by NVasc, Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Nervous …See details»
NVasc - Contacts, Employees, Board Members, Advisors & Alumni
NVasc is an early-stage ophthalmology company with a focus on treating blindness.See details»
Standards for Victim Assistance Programs and Providers
May 1, 2003 · Based on the work of the National Victim Assistance Standards Consortium, this report presents three sets of standards: Victim Assistance Program Standards, Competency …See details»
Steven Bettis - Founder & CEO @ NVasc - Crunchbase
Steven Bettis is the founder and Chief Executive Officer of NVasc, Inc. He previously worked at Anogen Life Sciences as a CEO. Steven Bettis attended the University of Tennessee, Knoxville.See details»
Standards for Victim Assistance Programs and Providers
After profiling the National Victim Assistance Standards Consortium, this report presents the Standards for Victim Assistance Programs and Providers developed by the Consortium, along …See details»